Anticorps Recombinant de lapin anti-SLC7A11/xCT
SLC7A11/xCT Recombinant Antibody for IF/ICC, FC (Intra), ELISA
Hôte / Isotype
Lapin / IgG
Réactivité testée
Humain et plus (1)
Applications
WB, IF/ICC, FC (Intra), ELISA
Conjugaison
Non conjugué
CloneNo.
230227C5
N° de cat : 82115-2-RR
Synonymes
Galerie de données de validation
Applications testées
| Résultats positifs en IF/ICC | cellules A549, |
| Résultats positifs en FC (Intra) | cellules A549, cellules HeLa |
Dilution recommandée
| Application | Dilution |
|---|---|
| Immunofluorescence (IF)/ICC | IF/ICC : 1:125-1:500 |
| Flow Cytometry (FC) (INTRA) | FC (INTRA) : 0.25 ug per 10^6 cells in a 100 µl suspension |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, check data in validation data gallery | |
Applications publiées
| WB | See 2 publications below |
| IF | See 1 publications below |
Informations sur le produit
82115-2-RR cible SLC7A11/xCT dans les applications de WB, IF/ICC, FC (Intra), ELISA et montre une réactivité avec des échantillons Humain
| Réactivité | Humain |
| Réactivité citée | Humain, souris |
| Hôte / Isotype | Lapin / IgG |
| Clonalité | Recombinant |
| Type | Anticorps |
| Immunogène | SLC7A11/xCT Protéine recombinante Ag25431 |
| Nom complet | solute carrier family 7, (cationic amino acid transporter, y+ system) member 11 |
| Masse moléculaire calculée | 55 kDa |
| Numéro d’acquisition GenBank | BC012087 |
| Symbole du gène | SLC7A11 |
| Identification du gène (NCBI) | 23657 |
| Conjugaison | Non conjugué |
| Forme | Liquide |
| Méthode de purification | Purification par protéine A |
| Tampon de stockage | PBS with 0.02% sodium azide and 50% glycerol |
| Conditions de stockage | Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20oC Les 20ul contiennent 0,1% de BSA. |
Informations générales
SLC7A11 (also known as xCT) is a membrane transporter involved in the uptake of cystine. It promotes glutathione synthesis through the uptake of cystine and the concomitant release of glutamate. This, in turn, protects cells from oxidative stress, maintains cellular redox balance, and prevents cell death induced by lipid peroxidation. SLC7A11 has been identified as a potential target for cancer therapeutics. It is overexpressed in multiple malignant tumors and is closely associated with the growth, prognosis, metastasis, and treatment response of various cancers including lung cancer.
Protocole
| Product Specific Protocols | |
|---|---|
| IF protocol for SLC7A11/xCT antibody 82115-2-RR | Download protocol |
| FC protocol for SLC7A11/xCT antibody 82115-2-RR | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
| Species | Application | Title |
|---|---|---|
Front Immunol A disulfidptosis-related lncRNA signature for analyzing tumor microenvironment and clinical prognosis in hepatocellular carcinoma | ||
Biofactors Induction of UBQLN1-mediated PGC1α stability by isoliensinine overcame hypoxia-induced resistance in liver cancer cells | ||
Ren Fail Dapagliflozin improves diabetic kidney disease by inhibiting ferroptosis through β-hydroxybutyrate production |



